1. Home
  2. ANIX vs GNT Comparison

ANIX vs GNT Comparison

Compare ANIX & GNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.81

Market Cap

100.6M

Sector

Health Care

ML Signal

HOLD

Logo GAMCO Natural Resources Gold & Income Trust

GNT

GAMCO Natural Resources Gold & Income Trust

HOLD

Current Price

$7.92

Market Cap

128.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIX
GNT
Founded
1982
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
100.6M
128.7M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ANIX
GNT
Price
$2.81
$7.92
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$8.67
N/A
AVG Volume (30 Days)
111.0K
54.8K
Earning Date
05-27-2026
01-01-0001
Dividend Yield
N/A
6.61%
EPS Growth
12.82
N/A
EPS
N/A
0.95
Revenue
$210,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.67
Revenue Growth
N/A
N/A
52 Week Low
$2.44
$5.99
52 Week High
$5.46
$9.30

Technical Indicators

Market Signals
Indicator
ANIX
GNT
Relative Strength Index (RSI) 43.41 30.98
Support Level $2.81 $7.76
Resistance Level $3.12 $8.06
Average True Range (ATR) 0.16 0.15
MACD -0.03 -0.05
Stochastic Oscillator 15.28 4.01

Price Performance

Historical Comparison
ANIX
GNT

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

About GNT GAMCO Natural Resources Gold & Income Trust

GAMCO Natural Resources, Gold & Income Trust is a non-diversified closed-end management investment company. The company's primary investment objective is to provide a high level of current income from interest, dividends, and options premiums with its secondary objective being capital appreciation. Under normal market conditions, the company invests majority of its assets in securities of companies principally engaged in the natural resources and gold industries, and also engages in writing covered call options on the underlying equity securities. Its portfolio consists of securities from different sectors such as metals and mining, energy and energy services, specialty chemicals, agriculture, healthcare, machinery, food and beverage, and others.

Share on Social Networks: